Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

New $3.5b AstraZeneca investment to accelerate US R&D and manufacturing

2
SHARES

This investment supports AstraZeneca’s strategy to drive the biopharma company’s development in the US.

AstraZeneca manufacturing R&D

Credit: grandbrothers / Shutterstock.com

To boost AstraZeneca’s research and manufacturing footprint by the end of 2026, it is dedicating $3.5 billion of capital investment in the US.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Of this amount, $2 billion will generate over 1,000 new jobs, the company added.

AstraZeneca highlighted its US footprint is expanding in multiple areas such as:
• a state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts
• next generation biologics manufacturing facility based in Maryland
• cell therapy manufacturing capacity on the West and East Coasts
• specialty manufacturing in Texas.

“By expanding our R&D and manufacturing footprint [with this multibillion-dollar investment], we aim to enhance the development of cutting-edge therapies and support the US leadership in healthcare innovation”

“By expanding our R&D and manufacturing footprint [with this multibillion-dollar investment], we aim to enhance the development of cutting-edge therapies and support the US leadership in healthcare innovation,” stated Pascal Soriot, Chief Executive Officer, AstraZeneca.

Overall, the biopharma firm explained that these initial US investments are part of AstraZeneca’s plan to attain $80 billion in Total Revenue by the end of the decade.

AstraZeneca’s investment in manufacturing

In August, AstraZeneca announced its single biggest investment in its Sweden Biomanufacturing Center in Södertälje, since the facility opened in 2021.

Financed with an extra $135 million, this will increase the biopharmaceutical facility area of AstraZeneca’s Sweden Biomanufacturing Center by 50 percent. The expansion is set to strengthen AstraZeneca’s capability to manufacture biologic medicines for patients worldwide.

Aligning with its commitment to investing in its future, at the time AstraZeneca shared this news, the company noted that more than fifty percent of its research projects were centred around biological drugs.

In February, the company shared that it planned to invest $300 million in a US-based manufacturing facility to “make next-generation cell therapy a reality”, according to Pam Cheng, Executive Vice President of Global Operations & IT and Chief Sustainability Officer, AstraZeneca.

Share via
Share via